Therapeutic Areas and Products
Tirofiban Premix 250 ml(in combination with heparin)is indicated for: patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events; treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy
Vernakalant hydrochloride 20mg/ml is indicated for: Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults who are hemodynamically stable
alendronate 70mg indicated for :treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures); Treatment to increase bone mass in men with osteoporosis.
orlistat 120mg is indicated for :treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors
Phytomenadione (2mg/ml,10mg/ml)is indicated for Prophylaxis and treatment of hemorrhagic disease of the newborn
Urokinase (10,000IU, 100,000IU, 250,000IU, 500,000IU) indicated for :Peripheral arterial thrombosis; Acute and subacute deep vein thrombosis; Acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable hemodynamic status; Thrombosed arteriovenous shunt
Crusia is indicated in adults for:•Prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery.•Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism.•Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), excluding PE ikely to require thrombolytic therapy or surgery. Prevention of thrombus formation in extra corporeal circulation during haemodialysis.•Acute coronary syndrome:-Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.-Treatment of acute ST-segment elevation myocardial infarction (STEMI) including patients to be managed medically or with subsequent percutaneous coronary intervention (PCI)
10mg pyridoxine hydrochloride &10mg doxylamine succinate are indicated for : the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
Urofollitrophin 75 IU is indicated for :the induction of ovulation in infertile women suffering from hypothalamus or hypophyseal disorders and in spanomenorrhoeic or amenorrhoeic women
Busulfan 60mg/10ml is indicated as a conditioning regimen prior to hematopoietic progenitor cell transplantation
Pegaspargase 750 IU/ml( solution for injection/infusion) is indicated for :treatment in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients
Tretinoin 10mg is indicated for :the induction of remission in acute promyelocytic leukemia
Gemcitabine hydrochloride (200mg,500,mg, 1000mg)is indicated for advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas ; bladder cancer ; recurrent or metastatic breast cancer; recurrent epithelial ovarian carcinoma
Hydroxycarbamide 500 mg is indicated for : chronic myeloid leukaemia (CML); essential thrombocythemia or polycythemia vera
Decarbazine citrate (200mg,500mg,1000mg) is indicated for : metastatic malignant melanoma ; advanced Hodgkin’s disease
Oxaliplatin is indicated for: stage III (Duke‘s C) colon cancer; metastatic colorectal cancer; metastatic pancreatic adenocarcinoma
Methotrexate (50mg/ml)is indicated for: severe psoriasis ; severe rheumatoid arthritis; severe, active juvenile idiopathic arthritis; Mild to moderate Crohn’s disease
Hepatitis b immunoglobulin 312IU/ml is indicated for : the Prevention of hepatitis B recurrence following liver transplantation
Ganciclovir 500mg IV is indicated for : CMV retinitis in immunocompromised patients; the prevention of CMV disease in transplant recipients
Orphan Drugs/Rare Diseases
Tzamal Biopharma manages its orphan-drug activities through Orphan Israel – Orphan Drugs for Rare Diseases Ltd. (a registered company).